Vor Ort
Merkzettel Warenkorb
Produktbild: Iaslc Thoracic Oncology

Iaslc Thoracic Oncology

279,99 €

inkl. gesetzl. MwSt., Versandkostenfrei

Beschreibung

Produktdetails

Einband

Gebundene Ausgabe

Erscheinungsdatum

20.06.2017

Verlag

Elsevier, München

Seitenzahl

704

Maße (L/B/H)

28,4/22,2/3,5 cm

Gewicht

1960 g

Auflage

2nd edition

Sprache

Englisch

ISBN

978-0-323-52357-8

Beschreibung

Rezension

"Overall, this is an outstanding resource that everyone interested in this subject must have.... The main objective of this book and the well-thought-out content sets it apart from any other book in the same space." Reviewed by Ravi Salgia, MD, PhD (City of Hope) Doody's Score: 98, 5 Stars!

Produktdetails

Einband

Gebundene Ausgabe

Erscheinungsdatum

20.06.2017

Verlag

Elsevier, München

Seitenzahl

704

Maße (L/B/H)

28,4/22,2/3,5 cm

Gewicht

1960 g

Auflage

2nd edition

Sprache

Englisch

ISBN

978-0-323-52357-8

Herstelleradresse

Libri GmbH
Europaallee 1
36244 Bad Hersfeld
DE

Email: gpsr@libri.de

Noch keine Bewertungen vorhanden

Verfassen Sie die erste Bewertung zu diesem Artikel

Helfen Sie anderen Kundinnen und Kunden durch Ihre Meinung.

Kundinnen und Kunden meinen

Bewertungen (0)
Die Leseprobe wird geladen.
  • Produktbild: Iaslc Thoracic Oncology

  • Section 1: Lung Cancer Control and Epidemiology

    1. Classical Epidemiology

    2. Tobacco Control and Primary Prevention

    3. Tobacco Cessation ¿

    4. Non-Smoking Related Lung Cancer

    5. Gender-Related Differences in Lung Cancer

    6. Genetic Susceptibility to Lung Cancer

    7. Early Detection and Radiologic Screening

    8. Preclinical Biomarkers for The Early Detection of Lung Cancer

    9. Chemoprevention of Lung Cancer: Present and Developing Technologies

    Section 2: Lung Cancer Molecular Carcinogenesis

    10. Copy Number Abnormalities and Gene Rearrangements in Lung Cancer: Present and Developing Technologies

    11. Mutational Events in Lung Cancer: Present and Developing Technologies

    12. Epigenetic Events, Alterations, and Remodeling in Lung Cancer: Present and Developing Technologies

    13. Stem Cells and Lung Cancer: In Vitro and In Vivo Studies

    14. Microenvironment and Lung Cancer¿¿

    15. MicroRNAs as Biomarkers for Lung Cancer

    Section 3: Immunology

    16. Humoral and Cellular Immune Dysregulation and Lung Cancer

    Section 4: Pathology

    17. Classic Anatomic Pathology and Lung Cancer

    18. Molecular Testing and Lung Cancer

    19. Management of the Small Biopsy in the Molecular Er¿¿

    Section 5: Clinical and Radiologic Presentation of Lung Cancer

    20. Clinical Presentation¿¿

    21. Conventional Imaging Lung Cancer

    22. PET Imaging of Lung Cancer

    Section 6: Diagnosis and Staging of Lung Cancer

    23. Diagnostic Work-Up of Suspected Lung Cancer

    24. Surgical Staging of the Mediastinum including Mediastinoscopy and Thoracoscopy, Preoperative and Intraoperative

    25. The 8th Edition of the Tumor, Node and Metastasis Classification of Lung Cancer

    Section 7: Surgical Management of Lung Cancer

    26. Preoperative Functional Evaluation of the Surgical Candidate¿¿

    27. Results of Video Assisted Techniques for Resection of Lung Cancer¿¿

    28. Results of Robotic Techniques for Resection of Lung Cancer

    29. Extent of Surgical Resection for Stage I and II Lung Cancer¿¿

    30. Extended Resections for Lung Cancer: Chest Wall and Pancoast Tumors¿¿

    31. Extended Resections for Lung Cancer: Broncho/Vascular Sleeve Resections

    32. Multiple Nodules: Management of the Patient with Synchronous or Metachronous Lung Cancers

    33. Surgical Management of the Marginally Resectable Patient

    Section 8: Radiotherapeutic Management of Lung Cancer

    34. Technical Requirements for Lung Cancer Radiotherapy

    35. Radiobiology of Lung Cancer

    36. Patient Selection for Radiotherapy¿

    37. Stage I Non-Small Cell Lung Cancer and Oligometastatic Disease

    38. Ablation Options for Localized Lung Cancer

    39. Radiotherapy for Locally Advanced Non-Small Cell Lung Cancer, including Combined Modality

    40. Radiotherapy in the Management of Small Cell Lung Cancer: Thoracic Radiotherapy, Prophylactic Cranial Irradiation

    41. Palliative Radiotherapy for Lung Cancer: Locoregional and Metastatic

    42. Acute and Late Toxicities of Thoracic Radiotherapy: Pulmonary, Esophagus, Heart

    43. Treatment-Related Neurotoxicity, Medical and Radiation Therapy

    Section 9: Chemotherapy and Targeted Agents for Lung Cancer

    44. Front-Line Systemic Options in Non-Small Cell Lung Cancer¿¿

    45. Systemic Options in Second Line and Beyond

    46. Maintenance Therapy in NSCLC

    47. Pharmacogenomics and Lung Cancer

    48. New Targetable Pathways in Lung Cancer

    49. Management of Toxicities of Targeted Therapies

    50. Immunotherapy and Lung Cancer

    51. Systemic Therapy in Early-Stage NSCLC

    52. Treatment of Small-Cell Lung Cancer

    Section 10: Other Thoracic Malignancies

    53. Malignant Mesothelioma

    54. Mediastinal Tumors

    55. Neuroendocrine Tumors of the Lung Other than SCLC

    56. Thymic Cancer/Thymoma

    Section 11: Symptom Management and Complications

    57. Lung Cancer Emergencies

    58. Role of Palliative Care in Lung Cancer

    Section 12: Clinical Trials

    59. Methodology of Clinical Trials in Lung Cancer¿

    60. How to Promote and Organize Clinical Research in Lung Cancer

    Section 13: Thoracic Oncology Advocacy

    61. Role of Advocacy Groups in Lung Cancer

    62. Health Services Research in Lung Cancer

    Appendix

    63. Appendix: Diagnostic Algorithms